IL131872A0 - Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors - Google Patents

Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Info

Publication number: IL131872A0
Authority: IL; Israel
Prior art keywords: benzothiepines; hmg; composition; bile acid; reductase inhibitors
Prior art date: 1997-03-11

Application number

IL13187298A

Other languages

English (en)

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-11

Filing date

1998-03-10

Publication date

2001-03-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131872(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-03-10 Application filed by Searle & Co filed Critical Searle & Co

2001-03-19 Publication of IL131872A0 publication Critical patent/IL131872A0/xx

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 title 1
239000003613 bile acid Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

IL13187298A 1997-03-11 1998-03-10 Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors IL131872A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4066097P	1997-03-11	1997-03-11
PCT/US1998/003792 WO1998040375A2 (en)	1997-03-11	1998-03-10	COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (1)

Publication Number	Publication Date
IL131872A0 true IL131872A0 (en)	2001-03-19

Family

ID=21912237

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13187298A IL131872A0 (en)	1997-03-11	1998-03-10	Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Country Status (16)

Country	Link
EP (1)	EP0971744A2 (pt)
JP (1)	JP2002500628A (pt)
CN (1)	CN1255864A (pt)
AU (1)	AU730024C (pt)
BG (1)	BG103793A (pt)
BR (1)	BR9808013A (pt)
CA (1)	CA2283575A1 (pt)
HU (1)	HUP0002395A3 (pt)
IL (1)	IL131872A0 (pt)
MX (1)	MXPA99008417A (pt)
NO (1)	NO994390L (pt)
NZ (1)	NZ337830A (pt)
PL (1)	PL336415A1 (pt)
RU (1)	RU2247579C2 (pt)
SK (1)	SK125099A3 (pt)
WO (1)	WO1998040375A2 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6083497A (en)	1997-11-05	2000-07-04	Geltex Pharmaceuticals, Inc.	Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
PT1140184E (pt)	1998-12-23	2003-10-31	Searle Llc	Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
AU2003241629B2 (en) *	1999-04-19	2005-06-16	Astrazeneca Ab	An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
AU2001247331A1 (en) *	2000-03-10	2001-09-24	Pharmacia Corporation	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (sv) *	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
WO2002051396A1 (en) *	2000-12-26	2002-07-04	Sankyo Company, Limited	Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en) *	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
WO2003022286A1 (en)	2001-09-08	2003-03-20	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
WO2003053368A2 (en)	2001-12-19	2003-07-03	Atherogenics, Inc.	Chalcone derivatives and their use to treat diseases
US7202247B2 (en)	2001-12-19	2007-04-10	Atherogenics, Inc.	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
US6852753B2 (en)	2002-01-17	2005-02-08	Pharmacia Corporation	Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
WO2004020421A1 (ja) *	2002-08-28	2004-03-11	Asahi Kasei Pharma Corporation	新規な４級アンモニウム化合物
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
CA2557576C (en)	2004-02-27	2010-02-09	Asahi Kasei Pharma Corporation	Novel benzothiazepine and benzothiepine compounds
WO2011150286A2 (en)	2010-05-26	2011-12-01	Satiogen Pharmaceuticals,Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SI3023102T1 (sl)	2010-11-04	2018-11-30	Albireo Ab	IBAT inhibitorji za zdravljenje jetrnih bolezni
CN103228270B (zh)	2010-11-08	2016-02-10	阿尔比里奥公司	含ibat抑制剂和胆汁酸结合剂的药物组合
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
BR112014010228B1 (pt)	2011-10-28	2020-09-29	Lumena Pharmaceuticals Llc	Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
RU2015139731A (ru)	2013-03-15	2017-04-20	ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи	Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
US20140271734A1 (en)	2013-03-15	2014-09-18	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
WO2015199147A1 (ja)	2014-06-25	2015-12-30	味の素株式会社	固形製剤及びその着色防止又は着色低減方法
CN115990171A (zh) *	2014-09-28	2023-04-21	华辉安健（北京）生物科技有限公司	聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
ES2874546T3 (es)	2016-02-09	2021-11-05	Albireo Ab	Formulación oral de colestiramina y uso de la misma
CN108601744B (zh)	2016-02-09	2022-01-04	阿尔比里奥公司	口服考来烯胺制剂及其用途
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
WO2019032026A1 (en)	2017-08-09	2019-02-14	Albireo Ab	CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CA3071182A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine pellets, oral cholestyramine formulations and use thereof
SG11202001685TA (en)	2017-08-28	2020-03-30	Enanta Pharm Inc	Hepatitis b antiviral agents
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019234077A1 (en)	2018-06-05	2019-12-12	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
ES3011850T3 (en)	2018-06-20	2025-04-08	Albireo Ab	Crystal modifications of odevixibat
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
IL283190B2 (en)	2018-11-21	2025-08-01	Enanta Pharm Inc	Functionalized heterocycles as antiviral agents
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
CA3127568A1 (en)	2019-02-06	2020-08-13	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
CN118834175A (zh)	2019-02-06	2024-10-25	阿尔比里奥公司	苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
BR112021015815A2 (pt)	2019-02-12	2022-01-18	Mirum Pharmaceuticals Inc	Métodos para tratar colestase
TWI867107B (zh)	2019-12-04	2024-12-21	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
JP7665620B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN114761080B (zh)	2019-12-04	2024-07-23	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TWI871392B (zh)	2019-12-04	2025-02-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TWI877263B (zh)	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	苯并噻二氮呯化合物及其作為膽酸調節劑之用途
TWI865673B (zh)	2019-12-04	2024-12-11	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP7695242B2 (ja)	2019-12-04	2025-06-18	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AR120674A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzotiazepina y su uso como ácido biliar
CA3186857A1 (en)	2020-08-03	2022-02-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (zh) *	2020-11-23	2022-10-14	郑州大学	一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
CA3198216A1 (en)	2020-12-04	2022-06-09	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en)	2022-06-09	2023-12-14	Albireo Ab	Treating hepatitis
TW202423921A (zh) *	2022-08-22	2024-06-16	美商安塔製藥公司	稠合的雜雙環抗病毒劑
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444784A (en) *	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
NZ245503A (en) *	1991-12-20	1995-11-27	Hoechst Ag	Polymers containing bile acids; pharmaceuticals and preparatory methods
GB9203347D0 (en) *	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds

1998
- 1998-03-10 CN CN98804995A patent/CN1255864A/zh active Pending
- 1998-03-10 SK SK1250-99A patent/SK125099A3/sk unknown
- 1998-03-10 HU HU0002395A patent/HUP0002395A3/hu unknown
- 1998-03-10 AU AU64408/98A patent/AU730024C/en not_active Ceased
- 1998-03-10 WO PCT/US1998/003792 patent/WO1998040375A2/en not_active Ceased
- 1998-03-10 EP EP98910075A patent/EP0971744A2/en not_active Withdrawn
- 1998-03-10 PL PL98336415A patent/PL336415A1/xx unknown
- 1998-03-10 CA CA002283575A patent/CA2283575A1/en not_active Abandoned
- 1998-03-10 NZ NZ337830A patent/NZ337830A/en not_active Application Discontinuation
- 1998-03-10 IL IL13187298A patent/IL131872A0/xx unknown
- 1998-03-10 JP JP53959498A patent/JP2002500628A/ja not_active Abandoned
- 1998-03-10 MX MXPA99008417A patent/MXPA99008417A/es unknown
- 1998-03-10 RU RU99121514/15A patent/RU2247579C2/ru not_active IP Right Cessation
- 1998-03-10 BR BR9808013-0A patent/BR9808013A/pt not_active IP Right Cessation
1999
- 1999-09-10 NO NO994390A patent/NO994390L/no not_active Application Discontinuation
- 1999-10-11 BG BG103793A patent/BG103793A/xx unknown

Also Published As

Publication number	Publication date
BG103793A (en)	2000-07-31
NZ337830A (en)	2001-07-27
EP0971744A2 (en)	2000-01-19
CN1255864A (zh)	2000-06-07
MXPA99008417A (es)	2005-02-03
PL336415A1 (en)	2000-06-19
NO994390L (no)	1999-11-04
RU2247579C2 (ru)	2005-03-10
CA2283575A1 (en)	1998-09-17
HUP0002395A2 (hu)	2001-05-28
NO994390D0 (no)	1999-09-10
JP2002500628A (ja)	2002-01-08
AU730024B2 (en)	2001-02-22
WO1998040375A2 (en)	1998-09-17
AU730024C (en)	2004-08-05
BR9808013A (pt)	2001-09-25
HUP0002395A3 (en)	2002-12-28
WO1998040375A3 (en)	1998-12-03
SK125099A3 (en)	2001-02-12
AU6440898A (en)	1998-09-29

Publication	Publication Date	Title
IL131872A0 (en)	2001-03-19	Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
SG108309A1 (en)	2005-01-28	Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
IL150104A0 (en)	2002-12-01	Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
HUP9903047A3 (en)	2002-12-28	Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
PL348609A1 (en)	2002-06-03	Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
IL144716A0 (en)	2002-06-30	Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
IL143947A0 (en)	2002-04-21	Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
HUP0104593A3 (en)	2004-10-28	Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications
EP0971723A4 (en)	2001-10-24	COMPOSITIONS AND METHODS FOR INHIBITING CELL PROLIFERATION
GR20010300025T1 (en)	2001-06-29	A system for electronic placement and broadcast of an advertisement
HUP0004533A3 (en)	2001-05-28	Microorganism reduction methods and compositions for food
IL130150A0 (en)	2001-03-19	Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
EP0737075A4 (en)	1998-09-09	COMPOSITIONS AND METHODS FOR TRANSPORTERS OF ILEAL BILIC ACID
AU6296198A (en)	1998-09-08	Dicarboxylic acid crystallizates
GB2319530B (en)	2001-06-13	Low toxic corrosion inhibitor
ZA988934B (en)	1999-03-31	Method and composition for inhibiting corrosion
AU4577999A (en)	2000-01-24	Methods and compositions for inhibiting corrosion
HUP0002103A3 (en)	2001-10-29	Hmg-coa reductase inhibitor preparation process
EP0913488A3 (en)	2003-01-29	Grain oriented electrical steel sheet and method
GB9612442D0 (en)	1996-08-14	Biodegradation of metal cyanides
HUP0201880A3 (en)	2003-03-28	Pharmaceutical composition containing sibutramine and a lipase inhibitor
HUP0201597A3 (en)	2003-04-28	Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
SI1091953T1 (en)	2004-06-30	Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
HK1057485A (en)	2004-04-08	Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
AU2399497A (en)	1998-11-27	Simple effective electronic ballast